Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

Gink­go Bioworks, a syn­thet­ic bi­ol­o­gy uni­corn that has cap­tured in­vestors’ imag­i­na­tions and trades un­der Genen­tech’s hal­lowed old $DNA tick­er, took a big blow Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.